553 related articles for article (PubMed ID: 30006410)
21. Single-center experience with intrathecal administration of Nusinersen in children with spinal muscular atrophy type 1.
Pechmann A; Langer T; Wider S; Kirschner J
Eur J Paediatr Neurol; 2018 Jan; 22(1):122-127. PubMed ID: 29208343
[TBL] [Abstract][Full Text] [Related]
22. Intrathecal delivery of nusinersen in individuals with complicated spines.
Cartwright MS; Ward ZT; White EP; West TG
Muscle Nerve; 2020 Jul; 62(1):114-118. PubMed ID: 32319101
[TBL] [Abstract][Full Text] [Related]
23. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
24. Managing intrathecal administration of nusinersen in adolescents and adults with 5q-spinal muscular atrophy and previous spinal surgery.
Mendonça RH; Fernandes HDS; Pinto RBS; Matsui Júnior C; Polido GJ; Silva AMSD; Grossklauss LF; Reed UC; Zanoteli E
Arq Neuropsiquiatr; 2021 Feb; 79(2):127-132. PubMed ID: 33759979
[TBL] [Abstract][Full Text] [Related]
25. Cone-beam computed tomography guided nusinersen administrations in adult spinal muscular atrophy patients with challenging access: a single- center experience.
Salapura V; Snoj Z; Leonardis L; Koritnik B; Kostadinova V
Radiol Oncol; 2022 Aug; 56(3):319-325. PubMed ID: 35962954
[TBL] [Abstract][Full Text] [Related]
26. Scoliosis Orthopedic Surgery Combined With Nusinersen Intrathecal Injection Significantly Improved the Outcome of Spinal Muscular Atrophy Patient: A Case Report.
Xu B; Wei C; Hu X; Li W; Huang Z; Que C; Qiu J; Li C; Xiong H
Front Neurol; 2022; 13():869230. PubMed ID: 35547367
[TBL] [Abstract][Full Text] [Related]
27. Nusinersen for the treatment of spinal muscular atrophy.
Chiriboga CA
Expert Rev Neurother; 2017 Oct; 17(10):955-962. PubMed ID: 28884620
[TBL] [Abstract][Full Text] [Related]
28. Ultrasound-guided transforaminal approach for nusinersen delivery in adult spinal muscle atrophy patients with challenging access.
Snoj Ž; Salapura V
Muscle Nerve; 2022 May; 65(5):585-589. PubMed ID: 35147227
[TBL] [Abstract][Full Text] [Related]
29. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
[TBL] [Abstract][Full Text] [Related]
30. Scoliosis and spinal muscular atrophy in the new world of medical therapy: providing lumbar access for intrathecal treatment in patients previously treated or undergoing spinal instrumentation and fusion.
Labianca L; Weinstein SL
J Pediatr Orthop B; 2019 Jul; 28(4):393-396. PubMed ID: 30932967
[TBL] [Abstract][Full Text] [Related]
31. Nusinersen for older patients with spinal muscular atrophy: A real-world clinical setting experience.
Veerapandiyan A; Eichinger K; Guntrum D; Kwon J; Baker L; Collins E; Ciafaloni E
Muscle Nerve; 2020 Feb; 61(2):222-226. PubMed ID: 31773738
[TBL] [Abstract][Full Text] [Related]
32. Nusinersen injections in adults and children with spinal muscular atrophy: a single-center experience.
Özütemiz C; Karachunski P; Nascene DR
Diagn Interv Radiol; 2020 Nov; 26(6):596-602. PubMed ID: 32436843
[TBL] [Abstract][Full Text] [Related]
33. Administration of nusinersen via paramedian approach for spinal muscular atrophy.
Iwayama H; Wakao N; Kurahashi H; Kubota N; Hattori A; Kumagai T; Okumura A
Brain Dev; 2021 Jan; 43(1):121-126. PubMed ID: 32773161
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of nusinersen in type 1, 2 and 3 spinal muscular atrophy: Real world data from Hungarian patients.
Szabó L; Gergely A; Jakus R; Fogarasi A; Grosz Z; Molnár MJ; Andor I; Schulcz O; Goschler Á; Medveczky E; Czövek D; Herczegfalvi Á
Eur J Paediatr Neurol; 2020 Jul; 27():37-42. PubMed ID: 32456992
[TBL] [Abstract][Full Text] [Related]
35. Restoration of Nusinersen Levels Following Treatment Interruption in People With Spinal Muscular Atrophy: Simulations Based on a Population Pharmacokinetic Model.
MacCannell D; Berger Z; Kirschner J; Mercuri E; Farrar MA; Iannaccone ST; Kuntz NL; Finkel RS; Valente M; Muntoni F
CNS Drugs; 2022 Feb; 36(2):181-190. PubMed ID: 35080757
[TBL] [Abstract][Full Text] [Related]
36. Nusinersen: First Global Approval.
Hoy SM
Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
[TBL] [Abstract][Full Text] [Related]
37. Successful Combination of Neuraxial and Regional Anesthesia in a Child With Advanced Spinal Muscular Atrophy Type 1 Receiving Maintenance Nusinersen Therapy: A Case Report.
Brown AF; Einhorn LM
A A Pract; 2020 Apr; 14(6):e01206. PubMed ID: 32784322
[TBL] [Abstract][Full Text] [Related]
38. The Complex Spine in Children with Spinal Muscular Atrophy: The Transforaminal Approach-A Transformative Technique.
Towbin R; Schaefer C; Kaye R; Abruzzo T; Aria DJ
AJNR Am J Neuroradiol; 2019 Aug; 40(8):1422-1426. PubMed ID: 31296522
[TBL] [Abstract][Full Text] [Related]
39. Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps.
Gidaro T; Servais L
Dev Med Child Neurol; 2019 Jan; 61(1):19-24. PubMed ID: 30221755
[TBL] [Abstract][Full Text] [Related]
40. Intrathecal nusinersen treatment for SMA in a dedicated neuromuscular clinic: an example of multidisciplinary and integrated care.
Sansone VA; Albamonte E; Salmin F; Casiraghi J; Pirola A; Bettinelli M; Rao F; Mancini L; Tovaglieri N; Fedeli F; Stoia P; Heinen M; Cozzi V; Carraro E; Lunetta C; Di Bari A; Mercuri E;
Neurol Sci; 2019 Feb; 40(2):327-332. PubMed ID: 30430317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
